The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure

17 May 2025 (16:00 - 16:45)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Ioan Radu Lala

Victor Babes Hospital, Timisoara (Romania)

4 More presentations in this session

Presentation thumbnail

Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?

Professor E. Kelepouris (Philadelphia, US)

Abstract Slides Video

Presentation thumbnail

Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.

Doctor A. Michel (Basel, CH)

Abstract Slides Video

Presentation thumbnail

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

Assistant Professor A. Sahin (Canakkale, TR)

Abstract Slides Video

Presentation thumbnail

Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)

Doctor G. Baudry (Nancy, FR)

Abstract Slides Video

Access the full session

Session thumbnail

Congestion, SGLT2 inhibitors and novel therapies

The Event

Event poster

Heart Failure 2025

17 May 2025 16:00 CET

You may be interested in

Congress Presentation

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

Congress Session

Decongestion in acute heart failure (1)

Congress Presentation

Management of acute and residual congestion in patients with acute heart failure by adding dapaglifozin to intravenous loop diuretic therapy-ENDORSE-HF

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources